Translational Lung Cancer Research
短名 | Transl Lung Cancer Res |
Journal Impact | 4.18 |
国际分区 | RESPIRATORY SYSTEM(Q1) |
期刊索引 | SCI Q2中科院 2 区 |
ISSN | 2218-6751, 2226-4477 |
h-index | 62 |
国内分区 | 医学(2区)医学肿瘤学(3区)医学呼吸系统(3区) |
TRANSLATIONAL LUNG CANCER RESEARCH (TLCR, TRANSL LUNG CANCER RES, PRINT ISSN 2218-6751; ONLINE ISSN 2226-4477) 是一本国际性、同行评议的开放获取期刊,创刊于 2012 年 3 月。TLCR 被 PUBMED/ PUBMED CENTRAL 和化学文摘服务 (CAS) 数据库。第一年每季度出版一次,自 2013 年 2 月起每双月出版一次。它提供有关肺癌预防、早期发现、诊断和治疗的实用最新信息。其感兴趣的具体领域包括但不限于多模式治疗、标志物、成像、肿瘤生物学、病理学、化学预防和与肺癌相关的技术进步。
期刊主页投稿网址涉及主题 | 医学内科学病理生物肿瘤科肺癌遗传学癌症外科化学生物化学放射科免疫学癌症研究哲学语言学肺生物信息学基因数学 |
出版信息 | 出版商: AME Publishing Company,出版周期: monthly,期刊类型: journal |
基本数据 | 创刊年份: 2012,原创研究文献占比: 92.43%,自引率:5.00%, Gold OA占比: 98.74% |
平均审稿周期 | 网友分享经验:In-house review: 1-3 weeksExternal peer review: 1-3 monthsPublication Ahead of Print: within 1 month after being accepted |
期刊引文格式
这些示例是对学术期刊文章的引用,以及它们应该如何出现在您的参考文献中。
并非所有期刊都按卷和期组织其已发表的文章,因此这些字段是可选的。有些电子期刊不提供页面范围,而是列出文章标识符。在这种情况下,使用文章标识符而不是页面范围是安全的。
只有1位作者的期刊
有2位作者的期刊
有3位作者的期刊
有5位以上作者的期刊
书籍引用格式
以下是创作和编辑的书籍的参考文献的示例。
学位论文引用格式
网页引用格式
这些示例是对网页的引用,以及它们应该如何出现在您的参考文献中。
专利引用格式
最新文章
Emphysema and lung cancer risk
2024-8-1
Are PD-1T TILs merely an expensive and unuseful whim as biomarker?
2024-8-1
Redefining YAP1 in small cell lung cancer: shifting from a dominant subtype marker to a favorable prognostic indicator
2024-8-1
Clinical features and prognostic biomarkers in patients with SMARCA4-mutated non-small cell lung cancer
2024-8-1
Single-center clinical experience of extended sleeve lobectomy (ESL) versus standard sleeve lobectomy (SL)
2024-8-1
Identifying genetically-supported drug repurposing targets for non-small cell lung cancer through mendelian randomization of the druggable genome
2024-8-1
Oncogene-addicted solid tumors and microbiome—lung cancer as a main character: a narrative review
2024-8-1
Clinical insights: five-year follow-up of KEYNOTE-189 trial outcomes and more
2024-8-1
Breaking barriers: patient-derived xenograft (PDX) models in lung cancer drug development—are we close to the finish line?
2024-8-1
Efficacy of ALK inhibitors in Asian patients with ALK inhibitor-naïve advanced ALK-positive non-small cell lung cancer: a systematic review and network meta-analysis
2024-8-1
Safety and efficacy of immunotherapy using a double-dose regimen in advanced non-small cell lung cancer (NSCLC): results of IDEE study
2024-8-1
CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study
2024-8-1
Prognostic role of dynamic changes in inflammatory indicators in patients with non-small cell lung cancer treated with immune checkpoint inhibitors—a retrospective cohort study
2024-8-1
Effective induction immunotherapy minimizes surgical invasiveness for locally advanced lung cancer
2024-8-1
Knowledge and beliefs about lung cancer screening among Black individuals at high risk: a qualitative approach
2024-8-1
Neutrophil estimation and prognosis analysis based on existing lung squamous cell carcinoma datasets: the development and validation of a prognosis prediction model
2024-8-1
Enhanced tumor targeting and penetration of fluorophores via iRGD peptide conjugation: a strategy for the precision targeting of lung cancer
2024-8-1
Assessing the transportability of radiomic models for lung cancer diagnosis: commercial vs. open-source feature extractors
2024-8-1
Effect of family history of cancer on postoperative survival in patients with non-small cell lung cancer
2024-8-1
Can a dysfunctional T-cell gene signature predict nonresponse to PD-1 blockade in non-small cell lung cancer?
2024-8-1
The (un)lucky seven—how can we mitigate risk factors for postoperative pneumonia after lung resections?
2024-8-1
REGN5093-M114: can an antibody-drug conjugate overcome the challenge of resistance to epidermal growth factor receptor and mesenchymal epithelial transition tyrosine kinase inhibitors in non-small cell lung cancer?
2024-8-1
A nomogram predicting the risk of extrathoracic metastasis at initial diagnosis of T≤3cmN0 lung cancer
2024-8-1
CT-based radiomic consensus clustering association with tumor biological behavior in clinical stage IA adenocarcinoma: a retrospective study
2024-8-1
Successful carinal reconstruction with right main bronchial flap rotational embedded augmentation: a case report
2024-8-1
Research into overcoming drug resistance in lung cancer treatment using CRISPR-Cas9 technology: a narrative review
2024-8-1
Prognostic and predictive significance of soluble programmed death ligand 1 in bronchoalveolar lavage fluid in stage IV non-small cell lung cancer
2024-8-1
LungPath: artificial intelligence-driven histologic pattern recognition for improved diagnosis of early-stage invasive lung adenocarcinoma
2024-8-1
Efficacy and prognostic factors of stereotactic body radiotherapy combined with immunotherapy for pulmonary oligometastases: a preliminary retrospective cohort study
2024-8-1
Immune-related osteoblastic bone alterations mimicking bone metastasis in a small-cell lung cancer patient treated with durvalumab: a case report
2024-8-1
Radiogenomics models for predicting prognosis in locally advanced non-small cell lung cancer patients undergoing definitive chemoradiotherapy
2024-8-1
Evaluation of the novel International Association for the Study of Lung Cancer grading system in adenocarcinoma with spread through air space
2024-8-1
Age at first sexual intercourse, age at menarche, and age at menopause: a mendelian randomization study on lung cancer risk
2024-7-1
Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer
2024-7-1
Timing of stereotactic radiosurgery within the first-line systemic treatment in non-small cell lung cancer brain metastases: a retrospective single-center cohort study
2024-7-1
Resected lung adenocarcinoma with lymph node metastasis: is ground glass opacity component a prognostic factor?
2024-7-1
Real-world biomarker testing patterns: clinical-pathological portrait of early and late non-small cell lung cancer in hub and spoke North Italian centers
2024-7-1
Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with rare KRAS mutations: a real-world retrospective study
2024-7-1
PD-L1 expression in non-small cell lung carcinoma in Latin America: a systematic review and meta-analysis
2024-7-1
Tumor cavitation in patients with non-small-cell lung cancer receiving anti-angiogenic therapy with apatinib
2024-7-1
Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases
2024-7-1
Association between thymus density loss and efficacy in non-small cell lung cancer patients treated with immune checkpoint inhibitors
2024-7-1
PD-L1 expression from surgically resected lung tumors predictive of early progression in patients previously treated with targeted therapy for initially unresectable non-small cell lung cancer
2024-7-1
Immunohistochemistry identifies E-cadherin, N-cadherin and focal adhesion kinase (FAK) as predictors of stage I non-small cell lung carcinoma spread through the air spaces (STAS), and the combinations as prognostic factors
2024-7-1
Association between strenuous sports or other exercises and lung cancer risk: a mendelian randomization study
2024-6-1
Predictive value of delta-radiomic features for prognosis of advanced non-small cell lung cancer patients undergoing immune checkpoint inhibitor therapy
2024-6-1
The APPLE trial in the evolving landscape of ctDNA monitoring
2024-6-1
Bioinformatics analysis of an immunotherapy responsiveness- related gene signature in predicting lung adenocarcinoma prognosis
2024-6-1
Clinical impact of EGFR and KRAS mutations in surgically treated unifocal and multifocal lung adenocarcinoma
2024-6-1
Radical resection in a patient with stage IIIA non-small cell lung cancer with the EGFR exon 19 deletion mutation after neoadjuvant targeted therapy with osimertinib: a case report
2024-6-1
帮你贴心管理全部的文献
研飞ivySCI,高效的论文管理
投稿经验分享
分享我的经验,帮你走得更远